Overview

Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
A Phase 3b, open-label, randomized, multicenter, safety and tolerability study of ITCA 650 in subjects with Type 2 diabetes taking liraglutide and metformin.
Phase:
Phase 3
Details
Lead Sponsor:
Intarcia Therapeutics
Treatments:
Exenatide
Liraglutide
Metformin